Biogen shares could rise on positive kidney and Alzheimer's trial data – Truist

Truist Securities analysts believe Biogen shares have room to rise if the company publishes positive results from ongoing clinical trials. The trials in question are linked to kidney disease and Alzheimer's treatments. Truist maintains an optimistic outlook on the biotechnology firm.